Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
深入了解百健股票：分析师观点（17 个评级）
Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
17位分析师提供的分析师对Biogen（纳斯达克股票代码：BIIB）在上个季度的评级从看涨到看跌不等。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表汇总了他们最近的评级，阐明了过去30天内情绪的变化，并将其与前几个月进行了比较。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $274.41, a high estimate of $364.00, and a low estimate of $200.00. Surpassing the previous average price target of $272.25, the current average has increased by 0.79%.
分析师分析的12个月目标股价提供了见解，平均目标股价为274.41美元，最高估计为364.00美元，低估值为200.00美元。超过了之前的平均目标股价272.25美元，目前的平均价格上涨了0.79％。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析师评级：详细审查
An in-depth analysis of recent analyst actions unveils how financial experts perceive Biogen...
对分析师近期行为的深入分析揭...
登录免费看全文
登录/注册